Tatva Chintan Pharma Chem Limited (TATVA) - Net Assets
Based on the latest financial reports, Tatva Chintan Pharma Chem Limited (TATVA) has net assets worth Rs7.54 Billion INR (≈ $81.58 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs9.08 Billion ≈ $98.17 Million USD) and total liabilities (Rs1.53 Billion ≈ $16.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Tatva Chintan Pharma Chem Limited to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs7.54 Billion |
| % of Total Assets | 83.11% |
| Annual Growth Rate | 43.43% |
| 5-Year Change | 345.17% |
| 10-Year Change | N/A |
| Growth Volatility | 57.02 |
Tatva Chintan Pharma Chem Limited - Net Assets Trend (2018–2025)
This chart illustrates how Tatva Chintan Pharma Chem Limited's net assets have evolved over time, based on quarterly financial data. See how many days can Tatva Chintan Pharma Chem Limited fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tatva Chintan Pharma Chem Limited (2018–2025)
The table below shows the annual net assets of Tatva Chintan Pharma Chem Limited from 2018 to 2025. For live valuation and market cap data, see TATVA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs7.39 Billion ≈ $79.90 Million |
+0.24% |
| 2024-03-31 | Rs7.37 Billion ≈ $79.71 Million |
+43.18% |
| 2023-03-31 | Rs5.15 Billion ≈ $55.67 Million |
+8.81% |
| 2022-03-31 | Rs4.73 Billion ≈ $51.16 Million |
+185.06% |
| 2021-03-31 | Rs1.66 Billion ≈ $17.95 Million |
+41.01% |
| 2020-03-31 | Rs1.18 Billion ≈ $12.73 Million |
+47.67% |
| 2019-03-31 | Rs797.00 Million ≈ $8.62 Million |
+34.73% |
| 2018-03-31 | Rs591.56 Million ≈ $6.40 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tatva Chintan Pharma Chem Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 504.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs3.09 Billion | 41.76% |
| Common Stock | Rs233.92 Million | 3.17% |
| Other Comprehensive Income | Rs25.08 Million | 0.34% |
| Other Components | Rs4.04 Billion | 54.73% |
| Total Equity | Rs7.39 Billion | 100.00% |
Tatva Chintan Pharma Chem Limited Competitors by Market Cap
The table below lists competitors of Tatva Chintan Pharma Chem Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Leysen Jewellery Inc
SHG:603900
|
$302.62 Million |
|
Ritek Corp
TW:2349
|
$302.69 Million |
|
T3EX Global Holdings Corp
TW:2636
|
$302.92 Million |
|
Funko Inc
NASDAQ:FNKO
|
$302.93 Million |
|
E Split Corp Class A
TO:ENS
|
$302.46 Million |
|
Iljin HySolus Co Ltd
KO:271940
|
$302.44 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
$302.41 Million |
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
$302.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tatva Chintan Pharma Chem Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,370,820,000 to 7,388,240,000, a change of 17,420,000 (0.2%).
- Net income of 57,130,000 contributed positively to equity growth.
- Dividend payments of 46,780,000 reduced retained earnings.
- Other comprehensive income increased equity by 14,119,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs57.13 Million | +0.77% |
| Dividends Paid | Rs46.78 Million | -0.63% |
| Other Comprehensive Income | Rs14.12 Million | +0.19% |
| Other Changes | Rs-7.05 Million | -0.1% |
| Total Change | Rs- | 0.24% |
Book Value vs Market Value Analysis
This analysis compares Tatva Chintan Pharma Chem Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 40.65x to 3.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | Rs29.43 | Rs1196.20 | x |
| 2019-03-31 | Rs39.68 | Rs1196.20 | x |
| 2020-03-31 | Rs58.59 | Rs1196.20 | x |
| 2021-03-31 | Rs82.62 | Rs1196.20 | x |
| 2022-03-31 | Rs220.05 | Rs1196.20 | x |
| 2023-03-31 | Rs232.25 | Rs1196.20 | x |
| 2024-03-31 | Rs322.02 | Rs1196.20 | x |
| 2025-03-31 | Rs315.55 | Rs1196.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tatva Chintan Pharma Chem Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.49%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.13x
- Recent ROE (0.77%) is below the historical average (18.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 20.79% | 9.05% | 0.94x | 2.44x | Rs63.78 Million |
| 2019 | 25.78% | 9.96% | 1.10x | 2.35x | Rs125.73 Million |
| 2020 | 32.11% | 14.36% | 1.06x | 2.12x | Rs260.20 Million |
| 2021 | 31.49% | 17.40% | 0.95x | 1.90x | Rs356.66 Million |
| 2022 | 20.27% | 22.11% | 0.66x | 1.39x | Rs485.65 Million |
| 2023 | 8.84% | 10.74% | 0.56x | 1.47x | Rs-59.92 Million |
| 2024 | 4.12% | 7.71% | 0.48x | 1.11x | Rs-433.54 Million |
| 2025 | 0.77% | 1.49% | 0.46x | 1.13x | Rs-681.69 Million |
Industry Comparison
This section compares Tatva Chintan Pharma Chem Limited's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $4,415,309,840
- Average return on equity (ROE) among peers: 15.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tatva Chintan Pharma Chem Limited (TATVA) | Rs7.54 Billion | 20.79% | 0.20x | $302.61 Million |
| Aarti Industries Limited (AARTIIND) | $3.75 Billion | 25.25% | 1.91x | $1.91 Billion |
| Aarti Surfactants Limited (AARTISURF) | $1.36 Billion | 4.04% | 1.96x | $35.50 Million |
| ABM International Limited (ABMINTLLTD) | $148.54 Million | -22.96% | 1.64x | $4.23 Million |
| Advanced Enzyme Technologies Limited (ADVENZYMES) | $8.67 Billion | 14.91% | 0.13x | $452.18 Million |
| Aether Industries Limited (AETHER) | $3.87 Billion | 28.16% | 0.99x | $1.66 Billion |
| Akzo Nobel India Limited (AKZOINDIA) | $8.48 Billion | 17.72% | 1.40x | $1.60 Billion |
| Alkali Metals Limited (ALKALI) | $293.96 Million | 25.87% | 0.91x | $9.63 Million |
| Alkyl Amines Chemicals Limited (ALKYLAMINE) | $11.69 Billion | 19.56% | 0.36x | $990.72 Million |
| Ami Organics Limited (AMIORG) | $822.19 Million | 28.33% | 1.59x | $1.18 Billion |
| Anupam Rasayan India Limited (ANURAS) | $5.07 Billion | 9.71% | 1.61x | $1.58 Billion |
About Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and br… Read more